Myconostica introduces new fungal pneumonia test
The assay, FXG: RESP (Asp +), uses real-time PCR technology to accurately and rapidly identify infections caused by both Aspergillus and Pneumocystis, the company said. According to the
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio.